Medtronic PLC’s recent decision to buy Stimgenics appears to be justified by the results of a clinical trial evaluating Medtronic’s Intellis spinal cord stimulation system programmed with Stimgenics’ differential target multiplexed (DTM) waveform to treat chronic back pain.
On 21 January, Medtronic announced that three-month results from the 94-patient randomized trial showed statistically significant and superior back...







